Table 1 Demographic and clinicopathological characteristics of the patients
From: Optimized radiotherapy to improve clinical outcomes for locally advanced lung cancer
Characteristic | SMART (n = 59) | H-RT (n = 14) | Total (n = 73) | |||
|---|---|---|---|---|---|---|
Age (years) | ||||||
Mean range | 65 | 65 | 66 | |||
Sex | ||||||
Male | 44 | 75% | 9 | 64% | 53 | 73% |
Mutation | ||||||
EGFR | 4 | 7% | 1 | 7% | 5 | 7% |
Smoking antecedent | ||||||
Yes | 40 | 68% | 10 | 71% | 50 | 68% |
Histologic type | ||||||
Adenocarcinoma | 31 | 53% | 8 | 57% | 39 | 53% |
Squamous | 24 | 41% | 6 | 43% | 30 | 41% |
Other | 4 | 7% | 0 | 0% | 4 | 5% |
AJCC stage | ||||||
Stage II | 5 | 9% | 3 | 21% | 8 | 11% |
Stage IIIA | 40 | 68% | 3 | 21% | 43 | 59% |
Stage IIIB | 12 | 20% | 2 | 14% | 14 | 19% |
Stage IV | 2 | 3% | 6 | 43% | 8 | 11% |
Chemotherapy type | ||||||
No chemotherapy | 4 | 7% | 6 | 43% | 10 | 14% |
Sequential chemotherapy | 11 | 19% | 8 | 57% | 19 | 26% |
Concurrent chemotherapy | 44 | 75% | 0 | 0% | 44 | 60% |
Chemotherapy agent | ||||||
Cisplatin-Vinorelbine | 27 | 46% | 0 | 0% | 27 | 37% |
Carboplatin-Taxol | 19 | 32% | 1 | 7% | 20 | 27% |
Other | 7 | 12% | 9 | 64% | 16 | 22% |
PTV volume (cm3) | ||||||
PTV 66 Gy | 287 | 337 | 335 | |||
PTV 54 Gy | 598 | 598 | ||||